Treatment of Diverticulitis Complicated by Cytomegalovirus Infection
For diverticulitis with CMV infection, treat with intravenous ganciclovir 5 mg/kg twice daily for 3-5 days, then transition to oral valganciclovir 900 mg twice daily for 2-3 weeks, while consulting infectious disease specialists early and considering withdrawal or tapering of immunosuppressive therapy.
Critical Context: This is NOT Standard Diverticulitis
The evidence provided addresses CMV colitis primarily in the context of inflammatory bowel disease (IBD), particularly ulcerative colitis, rather than true diverticulitis. However, the antiviral treatment principles remain consistent across gastrointestinal CMV infections.
Antiviral Treatment Regimen
The most recent guidelines 1, 2 consistently recommend:
- Initial therapy: IV ganciclovir 5 mg/kg twice daily for 5-10 days (some sources specify 3-5 days 3)
- Transition: Switch to oral valganciclovir 900 mg twice daily to complete a 2-3 week total course
- Earlier transition to oral therapy is acceptable based on clinical response 1
The 2021 ECCO guidelines 1 provide the most comprehensive and recent recommendations, extending the IV phase to 5-10 days compared to earlier 2016 guidelines 3 that suggested 3-5 days.
Management of Immunosuppression
For localized CMV colitis (the typical presentation):
- Immunosuppressants generally should NOT be discontinued 1
- Steroids should be tapered 1
- Many case series show immunosuppressants are maintained in most cases with successful outcomes 1
For disseminated CMV infection (fever, malaise, leukopenia, thrombocytopenia, elevated liver enzymes):
- Discontinue immunosuppressive therapy immediately 1
- This represents a medical emergency with high mortality risk
Key Clinical Considerations
Diagnostic Requirements
Before initiating treatment, confirm CMV through:
- Colonic biopsy with histology and immunohistochemistry (IHC) - gold standard 3
- Look for cytomegalic cells with "owl's eye" inclusions
- Support with colonic biopsy PCR and plasma PCR 3
Monitoring and Complications
Ganciclovir toxicity includes 1:
- Neutropenia and thrombocytopenia (which can also be CMV manifestations)
- Requires multidisciplinary management with infectious disease specialists
- Monitor complete blood counts closely
Alternative Agents
For ganciclovir-intolerant patients 1:
- Foscarnet: Requires strict renal function and electrolyte monitoring with IV saline co-administration
- Risk of genital ulceration from urinary excretion
- Maribavir: Emerging option for resistant/refractory cases 4, though not first-line
Special Populations
Immunocompromised patients (steroids, chemotherapy, transplant) 5:
- Have higher risk of severe/complicated disease
- Lower threshold for imaging and surgical consultation
- Longer antibiotic duration (10-14 days) for bacterial superinfection
- Consider elective resection after recovery
Surgical Considerations
Case reports 6, 7 demonstrate that:
- CMV can cause diverticular perforation even during ganciclovir treatment
- Highly localized CMV invasion may occur without widespread inflammation
- Surgical options include diverting ileostomy as alternative to total colectomy 7
- Early surgical consultation is essential for deteriorating patients 2, 8
Common Pitfalls
- Delaying antiviral therapy while awaiting confirmatory testing - start empirically if high suspicion
- Abruptly stopping all immunosuppression in localized disease - this may worsen underlying IBD
- Failing to distinguish localized CMV colitis from disseminated infection - management differs significantly
- Inadequate monitoring for ganciclovir toxicity
- Missing surgical window - deteriorating patients need colorectal surgery consultation early 2, 8